Abstract
Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in, we provide an overview of our efforts to develop clinically translatable PD-L1-specific imaging agents for quantitative and real-time assessment of PD-L1 expression in tumor microenvironment.
Original language | English (US) |
---|---|
Journal | Molecular imaging |
Volume | 16 |
DOIs | |
State | Published - Jul 5 2017 |
Keywords
- PD-1
- PET
- SPECT
- atezolizumab
- immunotherapy
- optical imaging
- peptide
ASJC Scopus subject areas
- Biotechnology
- Molecular Medicine
- Biomedical Engineering
- Radiology Nuclear Medicine and imaging
- Condensed Matter Physics